Continued Access to Deucravacitinib for Adult SLE/SjD and Pediatric PsO/PsA Study Completers
← catalyst calendarNCT07791199 · readout in 1,525 d
Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
Phase 3
Status
Not yet recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
2,300estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-27
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-09-02 | estimated | When the study began enrolling |
| Primary completion | 2030-10-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-10-31 | estimated | The whole study's end, after follow-up |
| First posted | 2026-08-27 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-27 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Systemic Lupus Erythematosus
- Sjögren's Disease
- Psoriasis
- Psoriatic Arthritis
Intervention
- Drug: Deucravacitinib
Primary outcome
what the primary-completion date above is the date OFNumber of participants treated
measured Up to approximately 28 days after last dose of deucravacitinib
Related
BMY · their whole pipeline · Systemic Lupus Erythematosus readouts · Congress trades in BMY · Executive-branch trades in BMY
BMY's other studiesmost recently updated first
- A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer Phase 3 · Active, not recruiting
- A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer Phase 3 · Terminated
- A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma Phase 3 · Active, not recruiting
- A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease Phase 3 · Recruiting
- A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma Phase 3 · Completed
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed